Nature of viruses and pandemics: Coronaviruses.

Autor:	Enjuanes L; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Sola I; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Zúñiga S; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Honrubia JM; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Bello-Pérez M; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Sanz-Bravo A; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., González-Miranda E; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Hurtado-Tamayo J; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Requena-Platek R; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Wang L; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Muñoz-Santos D; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Sánchez CM; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Esteban A; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain., Ripoll-Gómez J; Department of Molecular and Cell Biology. National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid. Darwin 3, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Current research in immunology [Curr Res Immunol] 2022; Vol. 3, pp. 151-158. Date of Electronic Publication: 2022 Aug 08.
DOI:	10.1016/j.crimmu.2022.08.003
Abstrakt:	Coronaviruses (CoVs) have the largest genome among RNA viruses and store large amounts of information without genome integration as they replicate in the cell cytoplasm. The replication of the virus is a continuous process, whereas the transcription of the subgenomic mRNAs is a discontinuous one, involving a template switch, which resembles a high frequency recombination mechanism that may favor virus genome variability. The origin of the three deadly human CoVs SARS-CoV, MERS-CoV and SARS-CoV-2 are zoonotic events. SARS-CoV-2 has incorporated in its spike protein a furine proteolytic site that facilitates the activation of the virus in any tissue, making this CoV strain highly polytropic and pathogenic. Using MERS-CoV as a model, a propagation-deficient RNA replicon was generated by removing E protein gene (essential for viral morphogenesis and involved in virulence), and accessory genes 3, 4a, 4b and 5 (responsible for antagonism of the innate immune response) to attenuate the virus: MERS-CoV-Δ[3,4a,4b,5,E]. This RNA replicon is strongly attenuated and elicits sterilizing protection after a single immunization in transgenic mice with the receptor for MERS-CoV, making it a promising vaccine candidate for this virus and an interesting platform for vector-based vaccine development. A strategy could be developed for the design of RNA replicon vaccines for other human pathogenic coronaviruses. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Luis Enjuanes has patent issued to PCT/ES2021/070378. Luis Enjuanes has patent issued to PCT/EP21383072.2. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu